Dr. Ying-Hsiu Su, Professor from the Baruch S. Blumberg Institute and Associate member of the Early Detection Research Network (EDRN) of the NCI, is one of few pioneers in the field of transrenal DNA for cancer detection. Dr. Su's lab first demonstrated that circulation-derived DNA in urine is mostly less than 300 bp, designated as low molecular weight urine DNA, which can be used for cancer detection. Dr. Su's research team has developed the technology to preferentially isolate this circulation derived urine DNA for detection of colon and liver cancers. In addition, a Standard Operating Protocol (SOP) for collection and storage of urine samples for biomarker studies in the EDRN of the NCI has been established by her group. Dr. Su has collaborated with Dr. Frank Song in developing various approaches to bring the transrenal DNA technology to clinical applications in the fields of cancer detection and personalized cancer management. Recently, the assays to detect CRC-associated hypermethylation of vimentin in urine of patients with CRC and HBV double mutations, p53 mutations in urine of patients with HCC have been developed in collaboration with the scientists of the JBS Science Inc.